Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A17-50
Last updated

Report documents

  1. Extract of dossier assessment

    Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 565 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 565 kB, EN, not accessible)

  2. Dossier assessment

    Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy

Result of dossier assessment:

Patients for whom treatment with docetaxel, pemetrexed or nivolumab is indicated: indication of a major added benefit (PD-L1 high) or non-quantifiable added benefit (PD-L1 low) Other patients: added benefit not proven.

Project details

Project no.
A17-50
Commission
Commission awarded on 29.09.2017 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-86
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-84
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-83
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-81
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A18-88
    Last updated

    Status: Commission completed

  6. Addendum

    Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50

    Project no.
    A18-09
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-52
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-51
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-102
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-97
    Last updated

    Status: Commission completed

  11. Dossier assessment

    Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-97
    Last updated

    Status: Commission completed

  12. Dossier assessment

    Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-67
    Last updated

    Status: Commission completed

  13. Dossier assessment

    Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-69
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page